ArticleThe patient2026
Recalibration: Exploring the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Self-Concept for Adults with Cystic Fibrosis.
Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic fibrosis (CF) is a progressive and multi-organ genetic condition most renowned for reduced lung function. The recent introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has transformed physical health and life expectancy for many people with CF.
objectivesThis mixed methods study aimed to compare levels of physical health and self-concept before and after ETI commencement and explore lived experiences of ETI impact on self-concept: an individual's overarching sense of identity.
methodsThis study applied a mixed methods approach, using qualitative data to enrich and augment the insights gained by the quantitative data. Longitudinal quantitative data were collected from 20 adults to compare mean lung function, frequency of pulmonary exacerbations, body mass index (BMI), and self-concept scores before and after ETI commencement. Qualitative data were collected from 13 of these adults through in-depth, unstructured interviews, which were thematically analysed to identify key insights.
resultsDescriptive and comparison statistical analysis demonstrated a significant increase in mean lung function and a significant decrease in mean frequency of pulmonary exacerbations following ETI commencement. No significant difference in BMI was identified. While mean self-concept scores before and after ETI commencement were not significantly different, thematic analysis of interview data highlighted that many participants had experienced self-concept recalibration across physical, social, and psychological domains of life related to ETI. The overarching theme of Self-concept recalibration and six subsequent themes emerged: Physical self: A 'new' CF and Weight gain - friend or foe; Social self: The gift of time and Goals and possibilities; and Psychological self: from Surviving to thriving and Into the unknown.
conclusionsFindings highlight significant physical health improvement for many people with CF, and the potential for ETI to positively impact self-concept. However, challenges and nuanced self-concept experiences were also identified. PRACTICE IMPLICATIONS: Integration of a self-concept approach to CF care is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.